
Hansa Biopharma
HNSA | ST
Overview
Corporate Details
- ISIN(s):
- SE0002148817 (+1 more)
- LEI:
- 549300LLEO25ZJJ3NT91
- Country:
- Sweden
- Address:
- Box 785, 220 07 Lund
- Website:
- https://www.hansabiopharma.com/
- Sector:
- Professional, scientific and technical activities
- Industry:
- Research and experimental development on natural sciences and engineering
Description
Hansa Biopharma is an innovative and rapidly growing biopharmaceutical company. Our vision is a world where all patients with rare immunologic diseases can lead long and healthy lives. But we often see that people with rare diseases are relegated to the impossible and left to fend for themselves. That’s not the way forward. We see all patients as equal individuals with individual needs. A point of view that gives us a unique ability to deliver the most inclusive care to everyone. For us the mission is clear – we want to develop lifesaving and life altering therapies to those who need them the most. And ultimately, we can – and will – eliminate rare diseases, one patient at a time. So how do we aim to achieve our goal? • We partner with global scientific, medical, and patient communities to identify the most urgent needs • We work relentlessly to meet the needs and create lifesaving treatments • Our lead program enables kidney transplantation in difficult-to-transplant patients
Market Data
Market Data Not Available
Financials & KPIs
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Date | Filing | Language | Size | Actions |
---|---|---|---|---|
2025-08-07 07:00 |
Regulatory News Service
Kallelse till extra bolagsstämma i Hansa Biopharma AB (publ)
|
Swedish | 295.0 KB | |
2025-08-07 07:00 |
Proxy Solicitation & Information Statement
Notice to Extraordinary General Meeting in Hansa Biopharma AB (publ)
|
English | 283.6 KB | |
2025-08-01 21:15 |
Inside Information Statement
Hansa Biopharma announces supportive data from treatment with imlifidase prior …
|
English | 246.4 KB | |
2025-08-01 21:15 |
Inside Information Statement
Hansa Biopharma tillkännager bekräftande resultat från behandling med imlifidas…
|
Swedish | 232.9 KB | |
2025-07-17 07:00 |
Quarterly Report
|
Swedish | 1.6 MB | |
2025-07-17 07:00 |
Interim Report
|
English | 1.4 MB | |
2025-07-01 22:04 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.8 KB | |
2025-07-01 14:59 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 9.5 KB | |
2025-06-30 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Hansa Biopharma: Ökning av antalet aktier och röster
|
Swedish | 208.0 KB | |
2025-06-30 07:00 |
Declaration of Voting Results & Voting Rights Announcements
Hansa Biopharma: Increase in number of shares and votes
|
English | 204.6 KB | |
2025-06-25 16:00 |
Declaration of Voting Results & Voting Rights Announcements
Kommuniké från årsstämma i Hansa Biopharma AB (publ)
|
Swedish | 231.8 KB | |
2025-06-25 16:00 |
Declaration of Voting Results & Voting Rights Announcements
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)
|
English | 247.2 KB | |
2025-06-25 11:25 |
Declaration of Voting Results & Voting Rights Announcements
|
Swedish | 11.6 KB | |
2025-06-19 01:21 |
Inside Information Statement
Hansa Biopharma has carried out a directed cash share issue of approx. mSEK 232…
|
English | 327.9 KB | |
2025-06-19 01:21 |
Inside Information Statement
Hansa Biopharma har genomfört en riktad kontantemission om ca 232 miljoner kron…
|
Swedish | 324.2 KB |
Insider Transactions
Date | Insider Name | Position | Type | Shares | Value |
---|---|---|---|---|---|
2024-06-17 | Anne Säfström Lanner | Other | Sell | 10,487 | 443,285.49 SEK |
2024-06-17 | Sören Tulstrup | Other | Sell | 9,199 | 388,841.73 SEK |
2024-06-17 | Sören Tulstrup | Other | Buy | 35,200 | N/A |
2022-07-19 | Peter Nicklin | Other | Buy | 14,500 | 1,032,192.68 SEK |
2022-06-17 | Christian Kjellman | Other | Buy | 6,915 | 345,680.85 SEK |
2022-06-17 | Donato Spota | Other | Sell | 4,638 | 231,853.62 SEK |
2022-06-17 | Christian Kjellman | Other | Sell | 4,002 | 200,059.98 SEK |
2022-06-17 | Sören Tulstrup | Other | Sell | 3,925 | 196,210.75 SEK |
2022-06-17 | Sören Tulstrup | Other | Buy | 3,925 | 196,210.75 SEK |
2022-06-17 | Anne Säfström Lanner | Other | Sell | 2,685 | 134,223.15 SEK |
Peer Companies
Company | Country | Ticker | View | |
---|---|---|---|---|
![]() |
1NKEMIA | Spain | IKM | |
![]() |
2cureX AB | Sweden | 2CUREX | |
![]() |
4SC AG | Germany | VSC | |
![]() |
Abera Bioscience AB | Sweden | ABERA | |
![]() |
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
![]() |
AB Science | France | AB | |
![]() |
Acticor Biotech | France | ALACT | |
![]() |
Active Biotech | Sweden | ACTI | |
![]() |
AcuCort AB | Sweden | ACUC |